Comparison of the prognosis of symptomatic cerebral infarction and pulmonary embolism in patients with advanced non-small cell lung cancer.
cerebral infarction
ischemic stroke
non-small cell lung cancer
pulmonary embolism
thromboembolism
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
revised:
03
12
2022
received:
06
08
2022
accepted:
13
01
2023
medline:
10
5
2023
pubmed:
29
1
2023
entrez:
28
1
2023
Statut:
ppublish
Résumé
Lung cancer patients face a high risk of thromboembolism (TE), which is considered to be a poor prognostic factor. However, the impact of symptomatic cerebral infarction (CI) and pulmonary embolism (PE) on the prognosis of advanced non-small cell lung cancer (NSCLC) patients is not fully understood. We retrospectively identified 46 patients with advanced NSCLC who developed symptomatic CI or PE at five hospitals in Japan between January 2010 and December 2019. Prognosis and biomarker levels after incident CI and PE were investigated. Of the 46 patients, 36 developed symptomatic CI, and 10 developed symptomatic PE. The median follow-up duration after incident CI and PE was 18.2 months. Although the proportion of Common Terminology Criteria for Adverse Events grade 4 tended to be higher in patients with PE than in those with CI (30% vs. 11%, p = 0.16), the overall survival (OS) after incident TE tended to be worse in patients with CI than in those with PE (median 2.3 months vs. 9.1 months, log-rank test p = 0.17). Multivariate analysis showed that OS after CI was worse in patients with high D-dimer (DD) levels than in those with low DD levels at the time of incident CI (median 1.3 months vs. 8.3 months, log-rank p < 0.001). This retrospective study demonstrated that the prognosis of patients tended to be poorer after CI than after PE. The DD levels at the time of incident CI might be a promising predictor of clinical outcomes in advanced NSCLC patients who develop CI.
Sections du résumé
BACKGROUND
Lung cancer patients face a high risk of thromboembolism (TE), which is considered to be a poor prognostic factor. However, the impact of symptomatic cerebral infarction (CI) and pulmonary embolism (PE) on the prognosis of advanced non-small cell lung cancer (NSCLC) patients is not fully understood.
METHODS
We retrospectively identified 46 patients with advanced NSCLC who developed symptomatic CI or PE at five hospitals in Japan between January 2010 and December 2019. Prognosis and biomarker levels after incident CI and PE were investigated.
RESULTS
Of the 46 patients, 36 developed symptomatic CI, and 10 developed symptomatic PE. The median follow-up duration after incident CI and PE was 18.2 months. Although the proportion of Common Terminology Criteria for Adverse Events grade 4 tended to be higher in patients with PE than in those with CI (30% vs. 11%, p = 0.16), the overall survival (OS) after incident TE tended to be worse in patients with CI than in those with PE (median 2.3 months vs. 9.1 months, log-rank test p = 0.17). Multivariate analysis showed that OS after CI was worse in patients with high D-dimer (DD) levels than in those with low DD levels at the time of incident CI (median 1.3 months vs. 8.3 months, log-rank p < 0.001).
CONCLUSIONS
This retrospective study demonstrated that the prognosis of patients tended to be poorer after CI than after PE. The DD levels at the time of incident CI might be a promising predictor of clinical outcomes in advanced NSCLC patients who develop CI.
Identifiants
pubmed: 36707978
doi: 10.1002/cam4.5647
pmc: PMC10166976
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9097-9105Informations de copyright
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Jpn J Clin Oncol. 2020 Oct 22;50(11):1246-1253
pubmed: 32715307
Ther Clin Risk Manag. 2018 Aug 01;14:1361-1368
pubmed: 30122935
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Ann Neurol. 2010 Aug;68(2):213-9
pubmed: 20695014
Cancer Med. 2023 Apr;12(8):9097-9105
pubmed: 36707978
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
JAMA. 2005 Feb 9;293(6):715-22
pubmed: 15701913
Arch Intern Med. 2008 Nov 24;168(21):2377-81
pubmed: 19029504
Cancer Res. 2016 Jul 1;76(13):3671-5
pubmed: 27527638
BMC Cancer. 2016 Mar 10;16:203
pubmed: 26964872
J Thromb Haemost. 2007 Mar;5(3):632-4
pubmed: 17319909
PLoS One. 2017 Mar 10;12(3):e0172793
pubmed: 28282388
J Stroke Cerebrovasc Dis. 2020 Oct;29(10):105164
pubmed: 32912544
Br J Clin Pharmacol. 2012 Aug;74(2):230-40
pubmed: 22320313
Stroke. 2019 Dec;50(12):e344-e418
pubmed: 31662037
Front Neurol. 2022 Apr 04;13:868137
pubmed: 35444612